CST, 87129T, RHAMM/CD168 (E7S4Y) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying RHAMM/CD168/HMMR. Validated for WB,IHC,IHC,IF,F. Available in 2 sizes. Highly specific and rigorously validated in-house, RHAMM/CD168 (E7S4Y) Rabbit Monoclonal Antibody (CST #87129) is ready to ship. Product Usage Information Western Blotting: 1:1000 IHC Leica Bond: 1:50 - 1:200 Immunohistochemistry (Paraffin): 1:50 - 1:200 Immunofluorescence (Immunocytochemistry): 1:50 - 1:200 Flow Cytometry (Fixed/Permeabilized): 1:100 - 1:200 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. For a carrier free (BSA and azide free) version of this product see product # 35364 . Protocol Available protocols: Western Blotting, IHC Leica Bond, Immunohistochemistry (Paraffin), Immunofluorescence (Immunocytochemistry), Flow Cytometry (Fixed/Permeabilized) Specificity / Sensitivity RHAMM/CD168 (E7S4Y) Rabbit Monoclonal Antibody recognizes endogenous levels of total RHAMM/CD168 protein. Non-specific staining was observed in kidney proximal tubules. Species Reactivity: Human, Mouse, Rat, Monkey Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human RHAMM/CD168 protein. The antigenic peptide spans a region that is 100% conserved among the four isoforms of RHAMM/CD168 reported in Uniprot. Background Receptor for Hyaluronic acid-Mediated Motility (RHAMM, known also as CD168 or HMMR) was first identified as a putative receptor for hyaluronic acid (HA) that modulated HA-mediated cell motility (1). RHAMM/CD168 is functionally similar to the HA receptor CD44; however in contrast to CD44, RHAMM/CD168 does not contain a transmembrane domain or a signal peptide leader sequence, and so is not targeted exclusively to the cell membrane (1). RHAMM/CD168 has multiple isoforms; some are reportedly exported to the cell membrane in response to signaling by growth factors and cytokines (e.g., TGF-β) (2, 3), whereas others have been implicated in intracellular functions including mitotic spindle regulation (4). Cell surface RHAMM/CD168 is localized to membrane ruffles, consistent with proteins that regulate cell motility (1). Numerous research studies have reported that the expression of RHAMM/CD168 is positively associated with cancer cell growth, motility and/or metastasis (5-7), in addition to HA-mediated inflammation (8), suggesting the potential for therapeutic approaches that target HA-receptor mediated signaling (9,10). Alternate Names CD168; HMMR; Hyaluronan mediated motility receptor; hyaluronan-mediated motility receptor (RHAMM); IHABP; intracellular hyaluronic acid binding protein; Intracellular hyaluronic acid-binding protein; MGC119494; MGC119495; Receptor for hyaluronan-mediated motility; RHAMM Specification REACTIVITY: H M R Mk SENSITIVITY: Endogenous MW (kDa): 85 Source/Isotype: Rabbit IgG